Abstract Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid
(CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly …

Neurodegenerative diseases are characterized by a progressive decline in brain function
and are a growing global threat (Jellinger, 2010). Early and accurate diagnosis of these …

Progressive loss of neurons in a specific brain area is one of the manifestations of
Alzheimer's disease (AD). Much effort has been devoted to investigating brain atrophy and …

Idiopathic Parkinson's Disease (iPD) is a common motor neurodegenerative disorder. It
affects more frequently the elderly population, causing a significant emotional burden both …

An accurate diagnosis of Alzheimer's disease (AD) currently stands as one of the most
difficult and challenging in all of clinical neurology. AD is typically diagnosed using an …

Background: Alzheimer's disease (AD) is a multifactorial process that takes years to manifest
clinically. We propose that brain-derived indicators of cerebrovascular dysfunction and …

Background: Wide-ranging functional defects in eye movements have been reported in
Alzheimer's disease (AD) dementia. The detection of abnormal eye movements and reading …

Since many years, magnetic resonance imaging (MRI) and positron emission tomography
(PET) have a prominent role in neurodegenerative disorders and dementia, not only in a …

Considering the high occurrence of neurodegenerative comorbidities, it is rather challenging
to clearly determine the precise diagnosis of normal pressure hydrocephalus (NPH), as well …

This paper explores the evolving landscape of Biomarkers in Alzheimer's disease (AD)
research, focusing on recent advancements in biomarker discovery, personalized medicine …